SCHEMBL3018670

SCHEMBL3018670

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(Cl)c(Cl)c3)CC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.38
ERBB2 P04626 4/20 0.38
EPHA2 P29317 4/20 0.38
KDR P35968 3/20 0.38
EPHB4 P54760 3/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 3/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015482 0.93 DRD2 (0.38) MEN1KMT2AMAPTUSP2RECQL
SCHEMBL3006479 0.91 MAPT (0.40) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL3019256 0.90 TSHR (0.39) MAPTUSP2RECQLHSD17B10KDM4E
SCHEMBL3011644 0.90 MAPT (0.36) MEN1KMT2AMAPTHSD17B10KDM4E
SCHEMBL3015567 0.90 HSD11B1 (0.38) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL3020128 0.90 MAPT (0.37) ERBB2EPHA2KDREPHB4MEN1
SCHEMBL2998369 0.90 RAB9A (0.37) ERBB2EPHA2KDREPHB4MAPT
SCHEMBL3007560 0.90 KDM1A (0.40) MEN1KMT2AMAPTHSD17B10ALDH1A1
SCHEMBL3014505 0.89 SCN1A (0.36) MEN1KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL3002832 0.88 TP53 (0.38) MEN1KMT2AMAPTRECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KCNA5 3217/4885ERBB2 3807/4885EPHA2 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.